Ooni Koda
  1. Home
  2. /
  3. Newsfeed
  4. /
  5. Biofarm records a net profit of 77 million...

Biofarm records a net profit of 77 million lei in 2023, up 9% compared to 2022

March 4, 2024

Biofarm, (stock symbol BIO), one of the most important drug manufacturers in Romania, ended 2023 with a net profit of about 77 million lei, up 9% from the previous year and a turnover of approx. 280 million lei, according to preliminary results (unaudited).

 

"In 2023, we successfully implemented cost optimization strategies, focusing in particular on two of our company values: performance and end-consumer care. In doing so, we were able to identify effective ways to control our expenses, even in the context of rising raw material and packaging prices. The Consumer Healthcare category in Romania is becoming more and more competitive year by year, marked also by a slight decline in volumes in 2023 compared to 2022. However, we ended 2023 managing to consolidate our position on the market, with a positive evolution of the volume market share and to contribute positively on the quality of life of patients and consumers in Romania", said Cătălin Vicol, Biofarm CEO.

 

Biofarm continued to strengthen its market share in the Consumer Healthcare (CHC) segment, and ended 2023 in second position in terms of number of units sold.

 

The company dominates in value in 6 key categories across brands: Bixtonim, Triferment, Colebil, Extravalerianic, Carmol and Carbocit. In addition, Biofarm is the volume leader in no less than 8 categories, highlighting the outstanding performance of the brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin. These results confirm the success of Biofarm's approach and commitment to innovation. Through its achievements, the company continues to establish itself as a trusted player in Consumer Healthcare, offering effective and affordable solutions to consumers.

 

Biofarm has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 100 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Constant innovation in the development of new products is one of the fundamental elements for Biofarm's expansion and strengthening its position among the leaders in the pharmaceutical industry.

The information provided by KomuniK

The text of this article has been partially taken from the publication:
https://komunik.ro/biofarm-records-a-net-profit-of-77-million-lei-in-2023-up-9-compared-to-2022/
Read in full - click here
Retail chain Metro responds to discrimination allegation voiced by Romanian jam producer

The high-end natural plum jam sold by Sonimpex under the brand Topoloveni is not in demand by the target market of Cash&Carry chain Metro – owners of small proximity stores and HoReCa firms, the German retail chain said in response to discrimination accusations expressed by the Sonimpex owner, quoted by

Romanian Liberal leader Nicolae Ciuca confirms plans to run for president this autumn

The leader of Romania's Liberal Party (PNL), Nicolae Ciuca, formerly prime minister and currently co-president of the country's ruling coalition, confirmed for Digi24 firm plans to run in the presidential elections this autumn. This should boost the party's score in the...

Amethyst invests EUR 10 mln to develop its fifth radiotherapy center in Romania

Amethyst Romania, a radiotherapy clinics chain set up by the entrepreneur Ludovic Robert, has started the EUR 10 million project of a new center in the northwestern part of the country at Satu Mare.  This will be the fifth Amethyst hospital dedicated to oncological treatments in Romania, after the existing units in Bucharest, Cluj-Napoca, Alba […]

Romania’s Romgaz prepares EUR 1.5 bln MTN scheme to finance Neptun Deep offshore project

Romania’s natural gas company Romgaz (BVB: SNG), with Rothschild Bank as its adviser, hired JP Morgan to lead the consortium of banks that will intermediate the sale of bonds on the foreign market under an MTN scheme aimed to finance the Black Sea gas project, Neptun Deep, Ziarul Financiar announced...

Romania ups MTN ceiling by EUR 7 bln to accommodate 2025 budget financing

The government of Romania took steps to increase the ceiling of the Medium Term Note (MTN) scheme by EUR 7 billion to EUR 75 billion, citing the EUR 8.5 billion financing needs in 2025 but also another EUR 0.6 billion-1.6 billion issues this year and potentially EUR 1 billion in case not all the Resilience […]

EU supports improved Ukrainian–Moldovan border crossing cooperation as part of Solidarity Lanes

  Thursday the European Commission, together with Ukraine, Moldova, Romania and the US are inaugurating the renewed Ukrainian-Moldovan border crossing point in Reni, Ukraine. As part of the Solidarity Lanes initiative, the Commission supported works on this border crossing point to allow for smoother traffic flow through the border as well as better connectivity between Ukraine, Moldova […]